| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G |
| 12 Nov 2026 |
Form 4: Cornelissen Bart Jan, SR. VICE PRESIDENT & CFO
Sold 10,100 shares ($402K) |
| 12 Nov 2026 |
Form 4: Ranieri Richard J, Director
Received 75,755 shares by exercise or conversion ($1.43M) · Sold 81,252 shares ($3.19M) |
| 12 Nov 2026 | 144 |
| 10 Nov 2026 | 144 |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
-- Updated results for XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma and outline of plans for potential registration-enabling development presented during ESMO -- |
| 30 Oct 2026 | SCHEDULE 13G/A |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 26 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
® Designing Proteins Delivering Medicines Updated Results from Dose Expansion Cohorts in the Phase 1 Study of XmAb819 October 26, 2026 |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
-- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- |
| 31 Jul 2026 | SCHEDULE 13G |
| 29 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties -- |
| 08 Jul 2026 |
Form 4: Feigal Ellen, Director
Received 10,302 shares as a grant or award · Granted 20,604 Stock Option (Right to Buy) |
| 08 Jul 2026 |
Form 4: Gorman Kevin Charles, Director
Received 10,302 shares as a grant or award · Granted 20,604 Stock Option (Right to Buy) |
| 08 Jul 2026 |
Form 4: Gustafson Kurt A, Director
Received 10,302 shares as a grant or award · Granted 20,604 Stock Option (Right to Buy) |
Loading...